Revolutionizing Prostate Cancer Therapy: Artificial intelligence – based Nanocarriers for Precision Diagnosis and Treatment

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104653 - 104653

Published: Feb. 1, 2025

Language: Английский

---

Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials

Frontiers in Nanotechnology, Journal Year: 2024, Volume and Issue: 6

Published: Oct. 21, 2024

Nanoparticles are attractive therapeutic tools due to their distinctive characteristics, including more accurate drug delivery, improved bioavailability, and enhanced targeted therapy. This review offers a comprehensive analysis of the potentials cutting-edge nanoparticles as demonstrated in human clinical trials, based on empirical evidence. Through systematic searches major scientific databases, relevant studies published up March 2024 were included, focusing trials utilizing advanced for purposes. The discusses diverse applications oncology, infectious diseases, neurology, other medical fields. Additionally, it scrutinizes safety profiles, efficacy outcomes, challenges associated with nanoparticle-based therapies. findings underscore significant progress translating nanoparticle research into practice highlight potential these innovative platforms revolutionize treatments. contributes valuable insights growing field therapeutics, fostering deeper understanding implications practice.

Language: Английский

---

Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(9), P. 1158 - 1158

Published: Sept. 1, 2024

Theranostics is a growing field that matches diagnostics and therapeutics. In this approach, drugs techniques are uniquely coupled to diagnose treat medical conditions synergically or sequentially. By integrating diagnostic treatment functions in single platform, the aim of theranostics improve precision medicine by tailoring treatments based on real-time information. context, lipid-based nanocarriers have attracted great scientific attention due their biodegradability, biocompatibility, targeting capabilities. The present review highlights latest research advances for cancer theranostics, exploring several ways improving vivo performance addressing associated challenges. These significant potential create new perspectives nanomedicine offer promise step towards more personalized precise medicine, reducing side effects clinical outcomes patients. This also presents actual barriers possible challenges use nanoparticles theranostic field, such as regulatory hurdles, high costs, technological integration. Addressing these issues through multidisciplinary collaborative approach among institutions could be essential advancing lipid field. Such collaborations can leverage diverse expertise resources, fostering innovation overcoming complex with translation. will crucial realizing full medicine.

Language: Английский

---

Global research trends and emerging hotspots in nano-drug delivery systems for lung cancer: a comprehensive bibliometric analysis (1998–2024)

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 11, 2025

Nano-drug delivery systems (NDDS) have become a promising alternative and adjunctive strategy for lung cancer (LC) treatment. However, comprehensive bibliometric analyses examining global research efforts on NDDS in LC are scarce. This study aims to fill this gap by identifying key trends, emerging hotspots, collaboration networks within the field of LC. A total 2452 publications, spanning from 1998 2024, were extracted Web Science Core Collection. The data analyzed using tools such as VOSviewer, CiteSpace, R package 'bibliometrix'. analysis covered contributions 12,539 researchers affiliated with 2689 institutions across 55 countries, their work published 551 different journals. Research output has increased steadily, China United States leading both publication volume impact. Major contributors include Chinese Academy Sciences Shanghai Jiao Tong University. International Journal Nanomedicine most articles, while Controlled Release ranked highest co-citations. Kamal Dua authored papers, Maeda, H. was frequently co-cited author. Key areas encompass "active targeting", "drug optimization", "overcoming drug resistance", "nanocarriers", "pulmonary delivery". Emerging hotspots "epithelial mesenchymal transition", "mucus penetration", "lipid nanoparticles", "hydrogels", "immune checkpoint inhibitors". analysis, first LC, identifies targeting" nanoparticles" These findings provide essential insights guide future optimize treatment strategies.

Language: Английский

---

A Comprehensive Review of Nanoparticle-Based Drug Delivery for Modulating PI3K/AKT/mTOR-Mediated Autophagy in Cancer

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 1868 - 1868

Published: Feb. 21, 2025

The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway plays a crucial role in regulation autophagy, cellular mechanism vital for homeostasis through degradation damaged organelles and proteins. dysregulation this is significantly associated with cancer progression, metastasis, resistance to therapy. Targeting PI3K/AKT/mTOR signaling presents promising strategy treatment; however, traditional therapeutics frequently encounter issues related nonspecific distribution systemic toxicity. Nanoparticle-based drug delivery systems represent significant advancement addressing these limitations. Nanoparticles enhance bioavailability, stability, targeted therapeutic agents, facilitating precise modulation autophagy cells. Functionalized nanoparticles, such as liposomes, polymeric metal-based nanocarriers, facilitate tumor tissues, minimizing off-target effects improving efficacy. These can deliver multiple agents concurrently, enhancing PI3K/AKT/mTOR-mediated oncogenic pathways. This review examines advancements nanoparticle-mediated that pathway, emphasizing their contribution precision side integration nanotechnology molecularly therapies substantial potential resistance. Future initiatives must prioritize optimization clinical translation patient outcomes.

Language: Английский

---

Advances in Materials Science for Precision Melanoma Therapy: Nanotechnology-Enhanced Drug Delivery Systems

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 296 - 296

Published: Feb. 24, 2025

Melanoma, a highly aggressive form of skin cancer, poses major therapeutic challenge due to its metastatic potential, resistance conventional therapies, and the complexity tumor microenvironment (TME). Materials science nanotechnology advances have led using nanocarriers such as liposomes, dendrimers, polymeric nanoparticles, metallic nanoparticles transformative solutions for precision melanoma therapy. This review summarizes findings from Web Science, PubMed, EMBASE, Scopus, Google Scholar highlights role in overcoming treatment barriers. Nanoparticles facilitate passive active targeting through mechanisms enhanced permeability retention (EPR) effect functionalization with tumor-specific ligands, thereby improving accuracy drug delivery reducing systemic toxicity. Stimuli-responsive systems multi-stage further improve overcome challenges poor penetration resistance. Emerging platforms combine diagnostic imaging delivery, paving way personalized medicine. However, there are still issues scalability, biocompatibility, regulatory compliance. comprehensive potential integrating genetics proteomics, scalable, patient-specific therapies. These interdisciplinary innovations promise redefine provide safer, more effective, accessible treatments. Continued research is essential bridge gap between evidence-based scientific clinical applications.

Language: Английский

---

Transforming cancer treatment: The potential of nanonutraceuticals

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 667, P. 124919 - 124919

Published: Nov. 7, 2024

Language: Английский

---

Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy

ACS Measurement Science Au, Journal Year: 2024, Volume and Issue: 5(1), P. 31 - 55

Published: Nov. 15, 2024

Cancer immunotherapy is an innovative way of treating cancer by stimulating individual cells to overcome cancer. Widespread biomedical studies were carried out with the aim exploring therapeutics, and this review spotlights some mechanisms in which it was developed, namely immune checkpoint inhibitors (E.G PD-1/PD-L1, CTLA-4), adoptive cell therapy (e.g., CAR T-cell therapy), vaccines. Although has shown clinical benefit a number types, including melanoma non-small-cell lung cancer, several challenges have dampened enthusiasm for approach, from differing patient response rates toxicities. Nanotechnology drug delivery systems must play role overcoming same. enables increased specificity controlled release, improved solubility bioavailability, can treat tumor specifically, localized at disease site decreases systemic toxicity. The also features advances construction lipid-based, polymeric, inorganic nanoparticles that improve stability allow cotherapeutic agents. Nanotechnology-based be used alone or combination assist improving response, gaining access microenvironment, biological barriers. Thus, nano-DDS both safe effective preclinical studies, ongoing trials they are capable increasing therapeutic index anticancer drugs. Lastly, discusses current regulatory issues advancing these technologies highlights importance further research devise appropriate methodology efficient functionalization nanotechnology individualized solutions treatment.

Language: Английский

---

Advancing brain immunotherapy through functional nanomaterials

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 9, 2025

Abstract Glioblastoma (GBM), a highly aggressive brain tumor, poses significant treatment challenges due to its immunosuppressive microenvironment and the immune privilege. Immunotherapy activating system T lymphocyte infiltration holds great promise against GBM. However, brain’s low immunogenicity difficulty of crossing blood-brain barrier (BBB) hinder therapeutic efficacy. Recent advancements in immune-actuated particles for targeted drug delivery have shown potential overcome these obstacles. These interact with BBB by rapidly reversibly disrupting structure, thereby significantly enhancing targeting penetrating delivery. The also minimizes long-term damage. At GBM, demonstrated effective chemotherapy, chemodynamic therapy, photothermal therapy (PTT), photodynamic (PDT), radiotherapy, or magnetotherapy, facilitating tumor disruption promoting antigen release. Additionally, components retained autologous tumor-associated antigens presented them dendritic cells (DCs), ensuring prolonged activation. This review explores mechanisms existing strategies, role nanomaterials immunotherapy. We discuss innovative particle-based approaches designed traverse mimicking innate functions improve outcomes tumors. Graphical

Language: Английский

---

Advancements in Nanotechnology for Targeted and Controlled Drug Delivery in Hematologic Malignancies: Shaping the Future of Targeted Therapeutics

Applied Biosciences, Journal Year: 2025, Volume and Issue: 4(1), P. 16 - 16

Published: March 5, 2025

Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, pose significant therapeutic challenges due to their heterogeneity high relapse rates. Nanotechnology has emerged as a promising avenue for precision drug delivery in these allowing enhanced concentration at tumor sites reducing systemic toxicity. Recent developments nanocarriers—such liposomes, polymeric nanoparticles, inorganic nanoparticles—have enabled targeted approaches, utilizing molecular markers specific malignant cells increase efficacy while minimizing adverse effects. Evidence from preclinical clinical studies underscores the potential of nanotechnology improve patient outcomes by facilitating controlled release, improved bioavailability, reduced However, translating advancements into practice requires further research validate safety efficacy. This review provides comprehensive analysis latest innovations hematologic addressing current achievements future directions integrating approaches Clinical Hemato-Oncology.

Language: Английский

---